Involvement of the Fanconi's anemia protein FAC in a pathway that signals to the cyclin B/cdc2 kinase

Cancer Research

Volumn 57, Issue 11, 1997, Pages 2244-2251

  Kruyt, Frank A E ^a   Dijkmans, Lonneke M ^a   Arwert, Fré ^a   Joenje, Hans ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; CYCLIN B; GENE PRODUCT; MITOMYCIN C; PROTEIN KINASE;

APOPTOSIS; ARTICLE; AUTOSOMAL RECESSIVE DISORDER; CANCER SUSCEPTIBILITY; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CHROMOSOME INACTIVATION; CROSS LINKING; DEPHOSPHORYLATION; DNA ADDUCT; DNA DAMAGE; FANCONI ANEMIA; HUMAN; HUMAN CELL; LYMPHOBLAST; LYMPHOBLASTOID CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

APOPTOSIS; CAFFEINE; CELL CYCLE; CELLS, CULTURED; CYCLIN-DEPENDENT KINASES; CYCLINS; FANCONI ANEMIA; FANCONI ANEMIA COMPLEMENTATION GROUP C PROTEIN; G2 PHASE; HUMANS; MITOMYCIN; MITOSIS; NUCLEIC ACID SYNTHESIS INHIBITORS; PHOSPHODIESTERASE INHIBITORS; PHOSPHORYLATION; PROTEINS; S PHASE; SIGNAL TRANSDUCTION; TYROSINE;

EID: 0030974684     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Liu, J. M., Buchwald, M., Walsh, C. E., and Young, N. S. Fanconi anemia and novel strategies for therapy. Blood, 84: 3995-4007, 1991.
2. Savitsky, K., Bar-Shira, A., Gilad, S., Rotman, G., Ziv, Y., Vanagaite, L., Tagle, D. A., Smith, S., Uziel, T., Sfez, S., Ashkenazi, M., Pecker, I., Frydman, M., Harnik, R., Patanjali, S. R., Simmons, A., Clines, G. A., Sartiel, A., Gatti, R. A., Chessa, L., Sanal, O., Lavin, M. F., Jaspers, N. G., Taylor, A. M. R., Arlett, C. F., Miki, T., Weissman, S. M., Lovett, M., Colins, F. S., and Siloh, Y. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science (Washington DC), 268: 1749-1753, 1995.
3. Ellis, N. A., Groden, J., Ye, T-Z., Straughen, J., Lennon, D. J., Ciocci, S., Proytcheva, M., and German, J. The Bloom's syndrome gene product is homologous to RecQ helicases. Cell, 83: 655-666, 1995.
4. Strathdee, C. A., Duncan, A. M. V., and Buchwald, M. Evidence for at least four Fanconi anaemia genes including FACC on chromosome 9. Nat. Genet., 1: 196-198, 1992.
5. Joenje, H., Lo Ten Foe, J. R., Oostra, A. B., van Berkel, C. G. M., Rooimans, M. A., Schroeder-Kurth, T., Wegner, R-D., Gille, J. J. P., Buchwald, M., and Arwert, F. Classification of Fanconi anemia patients by complementation analysis: evidence for a fifth genetic subtype. Blood, 86: 2156-2160, 1995.
6. Buchwald, M. Complementation groups: one or more per gene? Nat. Genet., 11: 228-230, 1995.
7. Strathdee, C. A., Gavish, H., Shannon, W. R., and Buchwald, M. Cloning of cDNAs for Fanconi's anaemia by functional complementation. Nature (Lond.), 356: 763-767, 1992.
8. Yamashita, T., Barber, D. L., Zhu, Y., Wu, N., and D'Andrea, A. D. The Fanconi anemia polypeptide, FACC, is localized to the cytoplasm. Proc. Natl. Acad. Sci. USA, 91: 6712-6716, 1995.
9. Youssoufian, H. Localization of Fanconi anemia C protein to the cytoplasm of mammalian cells. Proc. Natl. Acad. Sci. USA, 91: 7975-7979, 1995.
10. Youssoufian, H., Auerbach, A. D., Verlander, P. C., Steimle, V., and Mach, B. Identification of cytosolic proteins that hind to the Fanconi anemia complementation group C polypeptide in vitro. J. Biol. Chem., 270: 9876-9882, 1995.
11. Dutrillaux, B., Aurias, A., Dutrillaux, A. M., Briot, D., and Prieur, M. The cell cycle of lymphocytes in Fanconi anemia. Hum. Genet., 62: 327-332, 1982.
12. Kubbies, M., Schindler, D., Hoehn, H., Schinzel, A., and Rabinovitch, P. S. Endogenous blockage and delay of the chromosome cycle despite normal recruitment and growth phase explain poor proliferation and frequent endomitosis in Fanconi anemia cells. Am. J. Hum. Genet., 37: 1022-1030, 1985.
13. Kaiser, T. N., Lojewski, A., Dougherty, C., Juergens, L., Sahar, E., and Latt, S. A. Flow cytometric characterization of the response of Fanconi's anemia cells to mitomycin C treatment. Cytometry, 2: 291-297, 1982.
14. Seyschab, H., Friedl, R., Sun, Y., Schindler, D., Hoehn, H., Hentze, S., and Schroeder-Kurth, T. Comparative evaluation of diepoxybutane sensitivity and cell cycle blockage in the diagnosis of Fanconi anemia. Blood, 85: 2233-2237, 1995.
15. Kruyt, F. A, E., Dijkmans, L., van den Berg, T. K., and Joenje, H. Fanconi anemia genes act to suppress a p53-independent apoptosis pathway in lymphoblastoid cell lines. Blood, 87: 938-948, 1996.
16. Poll, E. H., Arwert, F., Joenje, H., and Wanamarta, A. H. Differential sensitivity of Fanconi anaemia lymphocytes to the clastogenic action of cis-diamminedichloroplatinum (II) and trans-diamminedichloroplatinum (II). Hum. Genet., 71: 206-210, 1985.
17. Youssoufian, H. Cytoplasmic localization of FAC is essential for the correction of prerepair defect in Fanconi anemia group C cells. J. Clin. Invest., 97: 2003-2010, 1996.
18. Pines, J. Cyclins and cyclin-dependent kinases: take your partners. Trends Biochem. Sci., 18: 195-197, 1993.
19. King, R. W., Jackson, P. K., and Kirschner, M. W. Mitosis in transition. Cell, 79: 563-571, 1994.
20. Hunter, T. Protein kinases and phophatases: the yin and yang of protein phosphorylation and signaling. Cell, 80: 225-236, 1995.
21. Draetta, G., and Beach, D. Activation of cdc2 protein kinase during mitosis in human cells: cell cycle-dependent phosphorylation and subunit rearrangement. Cell, 54: 17-26, 1988.
22. Morla, A. O., Draetta, G., Beach, D., and Wang, J. Y. J. Reversible tyrosine phosphorylation of cdc2: dephosphorylation accompanies activation during entry into mitosis. Cell, 58: 193-203, 1989.
23. cdc2. Cell, 58: 833-846, 1989.
24. cdc2. Cell, 63: 1013-1024, 1990.
25. cdc2 protein kinase in vertebrates. EMBO J., 10: 3321-3329, 1991.
26. cdc2 kinase activation in vertebrates. EMBO J., 10: 3331-3341, 1991.
27. cdc25 is a nuclear protein required for the initiation of mitosis in human cells. Proc. Natl. Acad. Sci. USA, 88: 10500-10504, 1991.
28. Galaktionov, K., and Beach, D. Specific activation of cdc25 tyrosine phosphatase by B-type cyclins: evidence for multiple roles of mitotic cyclins. Cell, 67: 1181-1194, 1991.
29. Glotzer, M., Murray, A. W., and Kirschner, M. W. Cyclin is degraded by the ubiquitin pathway. Nature (Lond.), 349: 132-138, 1991.
30. Lorca, T., Labbe, J-C., Devault, A., Fesquet, D., Capony, J-P., Cavadore, J-C., Le Bouffant, F., and Doree, M. Dephosphorylation of cdc2 on threonine 161 is required for inactivation and normal anaphase. EMBO J., 11: 2381-2390, 1992.
31. 2 arrest and DNA double-strand breaks. Cancer Res., 48: 4484-4488, 1988.
32. 2 arrest in Chinese hamster ovary cells. Cancer Res., 50: 3761-3766, 1990.
33. cdc2 tyrosine dephosphorylation, and mitotic progression in Chinese hamster ovary cells exposed to etoposide. Cancer Res., 52: 1817-1822, 1992.
34. cdc2/cyclin B. Cancer Res., 52: 1823-1829, 1992.
35. 2 delay induced by nitrogen mustard in human cells affects cyclin A/cdk2 and cyclin B1/cdc2-kinase complexes differently. J. Biol. Chem., 268: 8298-8308, 1993.
36. Ongkeko, W., Ferguson, D. J. P., Harris, A. L., and Norbury, C. Inactivation of cdc2 increases the level of apoptosis induced by DNA damage. J. Cell Sci., 108: 2897-2904, 1995.
37. Nicoletti, I., Migliorati, G., Pagliaccy, M. C., Grignani, F., and Riccardi, C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods, 139: 271-279, 1991.
38. 554-to-Pro substitution completely abolishes the functional complementing activity of the Fanconi anemia (FACC) protein. Hum. Mol. Genet., 2: 123-126, 1993.
39. cdc2/cyclin B complex. Proc. Natl. Acad. Sci. USA, 88: 6843-6847, 1991.
40. Chu, G. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J. Biol. Chem., 269: 787-790, 1994.
41. Harder, H. C., and Rosenberg, B. Inhibitory effects of antitumor platinum compounds on DNA, RNA, and protein synthesis in mammalian cells in vitro. Int. J. Cancer, 6: 207-216, 1970.
42. 2 checkpoint regulation. Blood, 88: 1019-1025, 1996.
43. Collins, M. K., Marvel, J., Malde, P., and Lopez-Rivas, A. Interleukin 3 protects murine bone marrow cells from apoptosis induced by DNA damaging agents. J. Exp. Med., 176: 1043-1051, 1993.
44. Isonishi, S., Jekunen, A. P., Hom, D. K., Eastman, A., Edelstein, P. S., Thiebaut, F. B., Christen, R. D., and Howell, S. B. Modulation of cisplatin sensitivity and growth rate of an ovarian carcinoma cell line by bombesin and tumor necrosis factor α. J. Clin. Invest., 90: 1436-1442, 1993.
45. Isonishi, S., Hom, D. K., Eastman, A., and Howell, S. B. Enhancement of sensitivity to platinum(II)-containing drugs by 12-O-tetradecanoyl-phorbol-13-acetate in a human ovarian carcinoma cell line. Br. J. Cancer, 69: 217-221, 1994.
46. Sanchez, Y., Desany, B. A., Jones, W. J., Liu, Q., Wang, B., and Elledge, S. J. Regulation of RAD53 by the ATM-like kinases MEC1 and TEL1 in yeast cell cycle checkpoint pathways. Science (Washington DC), 271: 357-360, 1996.
47. Beamish, H., Williams, R., Chen, P., and Lavin, M. Defect in multiple cell cycle checkpoints in ataxia-telangiectasia postirradiation. J. Biol. Chem., 271: 20486-20493, 1996.
48. Meyn, M. S. Ataxia-telangiectasia and cellular responses to DNA damage. Cancer Res., 55: 5991-6001, 1995.